Involved in therapeutic antibody R&D? Geneious Biologics screens and manages antibody sequence data in the cloud, transforming data management and significantly speeding up candidate selection. Learn more >
We make it easy
The user-friendly analysis and management tools in Geneious Prime help unlock the value in sequence data.
Painfree analysis with an intuitive, user-friendly interface
Increase process efficiency and improve data organisation
Cross-platform: Mac, Windows, Linux
Comprehensive support for technical issues, set up and training
“I have found Geneious to be one of the most intuitive and powerful sequence analysis programs that I have used in all my years working in the molecular biology field. Thanks for making my life so much easier.”
– Prof. John Payne, University of California
Everything you need, all in one place
Geneious Prime is a powerful bioinformatics software solution packed with fundamental molecular biology and sequence analysis tools
Molecular Cloning & Primer Design
Perform a wide-range of cloning and primer design operations within one interface.
NGS Analysis and Genomics
Take charge with industry-leading assembly and mapping algorithms, and superior visualizations.
Manage and store data effectively and get teams collaborating efficiently.
Import and Export Data
Import, export and convert common file types as well as their annotations and notes.
Save time and ensure your work is repeatable by creating or using in-built workflows.
API and Plugin Development
Integrate crucial operations using Geneious Prime’s API and Plugin Development tools.
“Geneious is an absolutely beautiful package to work with. We love it and we are telling everyone about it.”
– Charles Moore, Novartis Pharma AG, Switzerland
A History of Helping Scientists Innovate
“We created Geneious tools because we didn’t want our bright scientific minds spending 80 percent of their time doing basic data management. So we thought, if we can take away the pain and complexity of data computation and allow them to focus on what they’re really good at – which is understanding what that data means to uncover new scientific knowledge – then we’ve done our job.”
— Brett Ammundsen, Chief Executive Officer